Note: Eligibility for Samsung’s SmartStarts program requires newcomers to possess* one of the following Immigration, Refugees ...

Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of ...

Shares in Novo Nordisk have fallen by more than a quarter after the Ozempic maker revealed a set of underwhelming results in ...

The company plans to leverage research and development incentives from the Australian Government to offset the trial costs.

Novo Nordisk shares on the NYSE rose over 5% in premarket trading Monday, reversing some losses from Friday’s plunge that ...

Novo Nordisk plans a new trial for its experimental drug, CagriSema, in 2025 after recent trials failed to meet weight-loss expectations. Despite aiding patients to reduce weight by 22.7%, it fell ...

UBS analyst Trung Huynh says Novo Nordisk’s CagriSema Phase 3 topline obesity data “underwhelmed,” a positive read-through to Eli Lilly and Amgen . CagriSema achieved an ave ...

Novo Nordisk announced plans for a new trial of its CagriSema drug to explore its weight-loss potential further in 2025. The decision follows disappointing results from a late-stage trial that showed ...

Novo Nordisk executives set a high bar for itself when it projected CagriSema could achieve 25% weight loss. When the GLP-1 ...

Neurocrine Biosciences’ US FDA approved crinecerfont is available for children and adults to treat classic congenital adrenal hyperplasia: San Diego Tuesday, December 24, 2024, ...

In the latest Ozempic news, there are reports of people now 'microdosing' weight loss medications in order to lose weight and ...